SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
News | 04. 20. 2010
Liquidia Technologies
RESEARCH TRIANGLE PARK, N.C., April 20, 2010 --(EON: Enhanced Online News)-- Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
